Monitoring blood levels of DNA fragments shed by dying tumor cells may accurately predict skin cancer recurrence, a new study shows.

Merck & Co. Inc. (NYSE: MRK) is rewarding its shareholders once again with a quarterly dividend of $0.81 per share, payable ...

Merck & Co has a lower P/E than the aggregate P/E of 26.97 of the Pharmaceuticals industry. Ideally, one might believe that ...

Merck signs deal with Austria's Cyprumed to develop oral peptide therapies, potentially paying up to $493 million for access ...

Merck & Co.'s peptides could be undergoing a transformation into oral tablets thanks to a $493 million licensing deal the ...

We recently published a list of the 10 High Growth Forever Dividend Stocks to Invest In. In this article, we are going to ...

MSD obtains a Non-Exclusive License for Cyprumed’s delivery technology to develop oral peptide therapeuticsCyprumed will be eligible to receive ...

We recently published a list of the 11 Cheap NYSE Stocks to Invest in According to Hedge Funds. In this article, we are going ...

Merck is holding strong among billionaire favorites, despite the broader healthcare sector dodging investor affection like a ...

Trump on Tuesday said his administration will be announcing a “major” tariff on pharmaceuticals “very shortly.” ...

Semarion's SemaCyte® technology transforms adherent cell assays, enabling faster, automated workflows that enhance ...